PROTOX THERAPEUTICS ANNOUNCES PRESENTATION OF DATA AT LEADING CANCER RESEARCH CONFERENCE

Protox Therapeutics Inc. announced today that preclinical data demonstrating PRX302's validity as a treatment for prostate cancer and benign prostatic hyperplasia (BPH) is being presented in a poster session at the 97th Meeting of the American Association of Cancer Research (AACR), which is being held this week at the Washington Convention Centre in Washington, D.C.
CNW Group